This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Dechra's purchase of Elanco's Osurnia unit probed by UK CMA

( April 20, 2020, 06:33 GMT | Official Statement) -- MLex Summary: Dechra Pharmaceuticals' planned acquisition of Elanco Animal Health's Osurnia business is being probed by the UK Competition and Markets Authority, which started the clock on its investigation today. In January Dechra, a maker of veterinary pharmaceutical products, agreed to purchase Osurnia, Elanco's treatment for otitis externa in dogs, for $135 million. Elanco made the sale in order to push forward its acquisition of Bayer's animal-health business, which has received antitrust clearance in China, Turkey and Ukraine and is currently under review in multiple jurisdictions, including the US, Australia and Brazil. The deadline for the CMA's phase I decision is June 17.Statement follows...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login